Skip To Main Content
Ying-Long Peng on Muck Rack

Ying-Long Peng

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying-Long

Contact Ying-Long, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

AI-driven body composition atlas reveals its association with NSCLC immunotherapy outcome and molecular background: a multicenter study

|
By Yusheng Guo, Bingxin Gong, Jie Lou, Ying-Long Peng, Xiaoyan Lei, Peng Mo, Qi Wan, Qing Sun, Shu Peng, Chuansheng Zheng, Lian Yang
| Nature Verified
Abstract Although previous studies have linked body composition to immunotherapy efficacy, comprehensive multidimensional analyses with biological explanations remain lacking. This study integrated eight independent cohorts comprising 2,132 non-small cell lung cancer (NSCLC) patients, including five immune checkpoint inhibitor prognostic cohorts (n = 1,919), two bulk RNA-seq cohorts (n = 190), and one prospective single-cell RNA-seq cohort (n = 23).
Open in Who Shared Issue with article?

Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer - Nature Reviews Clinical Oncology

|
By Li-Bo Tang, Ying-Long Peng, Mei-Mei Zheng, Chong-Rui Xu
| Nature Verified
Abstract Lung cancer remains the leading cause of cancer-related mortality globally, with many patients diagnosed with advanced-stage disease. Treatment in this setting relies on systemic therapies, including chemotherapy, targeted therapy and immunotherapy. Immune-checkpoint inhibitors (ICIs), which promote or restore antitumour immunity by inhibiting immunosuppressive signalling pathways, are currently the most widely used immunotherapies in these patients.
Open in Who Shared Issue with article?

Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions

|
By Zi-Yan Wang, Ying-Long Peng, Ri-Wei Zhong, Shi-Qi Mei
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 3 articles